- Identification of the new ways of qualified and efficient drug/product development process
- How to make appropriate protocols that will manage the framework of investigators’ activities, their interactions, etc.
- Why should clinical trials be randomized?
- How can the integration of AI-based solutions improve the recruitment processes in clinical trials?
- How to develop a detailed guideline, so the site selection can be done systematically?
- Usage of creative recruitment methods to increase enrolment: personalized letters, websites, ads, local clinics’ involvement
- What will affect the study feasibility processes in 2023? How to prepare ourselves for these novelties?
- How to integrate the RWD & RWE in the CT and generate better results?
16th Annual Optimising Clinical Trials Summit:
Site Selection, Feasibility and Patient Recruitment
16-17 November 2022 | InterContinental Berlin
SEE THE PREVIOUS SPEAKERS & CASE STUDIES
Jose Manuel CERVERA GRAU
Marta GARCIA MANRIQUE
CONFERENCE TOPICS 2022
LOOK AT THE TOPICS THAT WERE DISCUSSED
Members of board, C-level, Senior/Global Vice Presidents, Directors, Heads of departments from the pharma industry involved in:
- Clinical Trials
- Clinical Operations
- Clinical Information
- Clinical Development
- Outsourced Trials
- Decentralized Trials
- Hybrid Trials
- Virtual Trials
- Randomized Trials
- Trial Management
- Clinical Study
- Safety Science
- Site Intelligence
- Patient Centricity
- Data Scientists
- R&D Informatics
- Clinical Innovations
- Site Management
- Clinical Management
- Clinical Research
- Global Safety
- Risk Monitoring
- Data Integrity
- Patient Recruitment
How Can the Integration of AI-Based Solutions Improve the Recruitment Processes in Clinical Trials?
New AI and blockchain-based solutions for clinical trials in healthcare are the new challenges for clinical trial (CT) designers and drug developers. It is necessary to know how these technologies will change CTs and what kind of tools will be implemented in traditional CTs. The high requirement for large numbers of patients to demonstrate sufficient efficacy to regulatory agencies is currently not a good optimisation. The limited number of patients due to advances in precision medicine will lead to the implementation of these technologies.
- Artificial Intelligence applied to CTs
- Blockchain applied to CTs
- NFTs applied to CTs
- Smart Contracts applied to CTs
Jose Manuel CERVERA GRAU
Igniting Excellence in Innovation through Outsourced Trials
- Looking at outsourced trials: Why are we doing this?
- Working with partnerships and optimize performance
- Highlighting key factors in making partnerships successful
Challenges and Opportunities in Pediatric Clinical Studies Compared to Adult Clinical Studies
I take this occasion to talk about pediatric clinical studies and to assess the main challenges and also the opportunities when these are compared with adult studies. I will look into this landscape and as an example I will use a case report for a currently ongoing clinical study to be conducted on children and adolescents with secondary hyperthyroidism and vitamin D deficiency.
- Ethics in clinical trials
- Definition of vulnerable groups
- Pediatric studies, including regulations
- Pediatric and Adult studies: main differences, challenges and opportunities
- Conclusions and Take-home messages
Marta GARCIA MANRIQUE
Insights on the Patient Centricity
- Keeping the patient at the centre of your actions. How to ensure that CT outcome matters to patients?
- Patient communication enhancement at all the levels of the CT. Will it enable a conscious, well-in-formed decision about the study participation?
- Can a virtual trial become a solution for patients to join a trial?
- How to facilitate the acknowledgment of the patients’ effort in a CT and create a positive experience
Understanding Patients´ Needs During Drug Development: The Patient Safety Perspective
When prescribing an innovative medication, physicians together with their patients make a benefit-risk evaluation based on the drug´s potential benefits and also outweigh the potential risks experienced by study patients. This patient’s experienced value of the new health technology is a requirement and precondition for regulatory and payer approval. So, how and when to engage patients?
The drug developer should recognize the value of patient’s involvement from the very beginning, even before the product enters clinical development and should continue across the entire life cycle and work to adapt present perceptions and practices throughout their organizations. Supposed individual patient’s needs and perspectives are put at the heart of all efforts from clinical development to regulatory approval and HTA. In that case, these insights should be shared with patients and prescribers to better inform and guide treatment decisions, thus enhance patient-centred care and personalized medicine.
- Pharmaceutical development has to demonstrate the value of the new health technology relative to the outcomes experienced by patients
- Patient engagement works, when the involvement starts already during the early stages of development
”Thank you! I have learned a lot and took away a lot of insights I can share with my colleagues. I have to say the variety of sessions and the presenters exceeded my expectations.– Associate Director, Clinical Project Manager, Teva Pharmaceutical Industries
STAY UPDATED FOR THE 2023 EDITION
Provide Us With Your Contact Details and Our Team Will Get Back to You With All the Updates Regarding the Upcoming Edition of This Event.